Next Generation ALK Inhibitors to Improve the Life of Patients having ALK-Positive NSCLC

Release Date: 24-Nov-2020

Certain safety profiles have been developed by combining eganelisib (IPI-549), a selective PI3K-andgamma; inhibitor, and nivolumab (Opdivo) in the patients suffering from head and neck squamous cell carcinoma. All the patients that were enrolled in the respective study received higher response rate. Some of primary aim of the researchers were to calculate partial response (PR) rate, disease control rate. Among the patients that were enrolled in the study, 2 patients achieved a partial response (PR) and 2 achieved stable disease (SD).


The significant demand of efficient treatment for cancers such as head and neck cancer as well as melanoma has increased in the past few years, especially those who are refractory to antiandndash;PD-1 antibodies. The drug eganelisib is observed to relieve immuno suppression by performing changes in the myeloid-derived suppressor cells. The overall mechanism of the drug also allows activation of the T cells against the cancer. Therefore, it was predicted that the rational combination of the drug could be used for achieving greater anti-tumor impact.


The combination of the drug that has been used in the treatment of the patients suffering from head and neck cancer was also confirmed in the treatment of the patients suffering from melanoma. The clinical results achieved for melanoma were highly inspiring as the total benefits that were received from the combination were way higher when compared with the healthcare benefits that other commercial therapies have been providing to the cancer patients. Some of the other cancer types for which the combination is getting evaluated are: nonandndash;small cell lung cancer, triple-negative breast cancer adrenocortical carcinoma, mesothelioma. The overall combination of the drug is believed to accelerate the overall growth of the cancer therapeutics market.

Need custom market research solution? We can help you with that too.